Bitdeer Technologies Group vs Nuwellis Inc — how do they compare? Bitdeer Technologies Group trades at $12.5 (market cap $3.01B), while Nuwellis Inc trades at $3.36 (market cap $1.17M). The key difference: Bitdeer Technologies Group is far larger — about 2572.6× Nuwellis Inc's market cap, and Bitdeer Technologies Group is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| BTDR | NUWE | |
|---|---|---|
Market Cap | $3.01B | $1.17M |
Sector | Technology | Technology |
52-Week High | $25.90 | $558.26 |
52-Week Low | $7.28 | $2.80 |
Enterprise Value | $4.77B | -$636.97K |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.
The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →